March 12 (Reuters) - Hikma Pharmaceuticals Plc's full-year profit more than doubled helped by strong demand andhigher prices for the antibiotic doxycycline that is used in thetreatment bacterial infections including Lyme disease.
The company, which makes and markets branded and non-brandedgenerics and injectibles, reported an adjusted profitattributable to shareholders of $274 million compared with $120million a year earlier.
Revenue for the year ended Dec. 31 rose 23 percent to $1.37billion, in line with the company's estimate last month.
Hikma, which has grown over the past year due to a shortageof doxycycline in the United States, said generics revenue rose158 percent to $268 million for the year.
Shares in the Jordanian company closed at 1473 pence onTuesday on the London Stock Exchange.
Hikma Pharmaceuticals (HIK)
